Anti cd8 pcd

The analyses of the first stroke cohort (Table 1) included evaluation of leukocytes, neutrophils, T cells, CD4 + T cells, CD8 + T cells, NK cells and B cells (anti-CD45 FITC, clone: B3821F4A; anti-CD56 PE, clone: N901/NKH-1; anti-CD16 PE, clone: 3G8, anti-CD19 ECD, clone: J3-119; anti-CD4 PE, clone: SFCI12T4D11; anti-CD8 PCD, clone: SFCI21Thy2D3; and anti-CD3_PC5, clone: UCHT1 [Beckman Coulter, Krefeld]) on days 0, 1, 2, 3, 4, 5, 7 post stroke. Cell analysis was performed on an FC500 (Beckmann Coulter, Krefeld) flow cytometer in the Department of Oncology of the University Medicine Greifswald. Cells were analysed on day of blood collection. Since all population could be clearly identified by the mentioned marker above no isotype controls were used.

Fluorescence-activated cell sorting was used to measure cell counts for leukocytes, neutrophils, T cells, CD4+T cells, CD8+T cells, NK cells, and B cells (anti-CD45 FITC; anti-CD56 PE, anti-CD16 PE, anti-CD19 ECD, anti-CD3 PC5, IgG1 PC7, anti-CD4 PE, anti-CD8 PCD, anti-CD3 PC5 [Beckman Coulter]).

Differential blood cell counts (XN9000, Sysmex, Norderstedt, Germany), PCT and CRP (Adivia Centaur XPT and Dimension Vista, Siemens Healthcare Diagnostics, Eschborn, Germany) were determined. Fluorescence-activated cell sorting was used to measure cell counts for leukocytes, T-cells, CD4+T-cells, CD8+T cells, NK cells and B cells as well as HLA-DR on T-cells (anti-CD45 FITC; anti-CD56 PE, anti-CD19 ECD, anti-CD3 PC5, IgG1 PC7, anti-CD4 PE, anti-CD8 PCD, anti-CD3 PC5, anti-HLA-DR-PE [FC500; Beckman Coulter]).